2-189008960-G-A
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Moderate
The ENST00000304636.9(COL3A1):c.3562G>A(p.Gly1188Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1188E) has been classified as Pathogenic.
Frequency
Consequence
ENST00000304636.9 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL3A1 | NM_000090.4 | c.3562G>A | p.Gly1188Arg | missense_variant | 48/51 | ENST00000304636.9 | NP_000081.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL3A1 | ENST00000304636.9 | c.3562G>A | p.Gly1188Arg | missense_variant | 48/51 | 1 | NM_000090.4 | ENSP00000304408 | P1 | |
COL3A1 | ENST00000450867.2 | c.3463G>A | p.Gly1155Arg | missense_variant | 47/50 | 1 | ENSP00000415346 | |||
COL3A1 | ENST00000487010.1 | n.659G>A | non_coding_transcript_exon_variant | 1/3 | 2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 24, 2016 | The p.G1188R pathogenic mutation (also known as c.3562G>A), located in coding exon 48 of the COL3A1 gene, results from a G to A substitution at nucleotide position 3562. The glycine at codon 1188 is replaced by arginine, an amino acid with dissimilar properties. The majority (approximately two-thirds) of COL3A1 mutations identified to date have involved the substitution of another amino acid for glycine within the triple-helical domain (Schwarze U et al. Am J Hum Genet. 1997;61(6):1276-1286; Pepin MG et al. Genet Med. 2014;16(12):881-8). The p.G1188R mutation (reported with the legacy nomenclature p.G1021R) has been detected in two unrelated individuals with Ehlers-Danlos syndrome type IV (EDS IV), and cultured skin fibroblasts from both patients have been shown to produce abnormal type III procollagen (Pope FM et al. Br. J. Dermatol. 1996;135:163-81; Pepin M et al. N. Engl. J. Med. 2000;342:673-80). In addition, two other alterations associated with EDS IV, p.G1188V and p.G1188E, have been described in the same codon (Narcisi P et al. Am. J. Med. Genet. 1993;46:278-83; Drera B et al. J. Dermatol. Sci. 2011;64:237-40). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Ehlers-Danlos syndrome, type 4 Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Collagen Diagnostic Laboratory, University of Washington | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at